HC Wainwright Forecasts Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Shattuck Labs in a research note issued on Thursday, March 27th. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.40) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($2.00) EPS.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%.

Other research analysts have also recently issued research reports about the company. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a report on Thursday. Finally, Leerink Partners assumed coverage on Shattuck Labs in a research note on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target on the stock. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Price Performance

STTK stock opened at $1.06 on Monday. The firm has a market cap of $50.37 million, a PE ratio of -0.69 and a beta of 1.66. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76. The firm has a 50 day simple moving average of $1.24 and a 200 day simple moving average of $1.46.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently modified their holdings of STTK. Zacks Investment Management acquired a new position in Shattuck Labs in the fourth quarter valued at about $25,000. Virtu Financial LLC bought a new position in shares of Shattuck Labs in the fourth quarter worth about $30,000. Atom Investors LP acquired a new position in shares of Shattuck Labs during the third quarter worth approximately $35,000. Readystate Asset Management LP bought a new stake in shares of Shattuck Labs during the third quarter worth $39,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Shattuck Labs in the fourth quarter valued at about $45,000. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.